NZMS Diabetes
NZMS Diabetes is a wholly-owned Dexcom subsidiary that exclusively distributes Dexcom CGM systems and Tandem insulin pumps to New Zealanders with Type 1 diabetes through Pharmac-funded prescriptions and local pharmacies.
- Company typePrivate
- Founded1982
- HeadquartersAuckland, New Zealand
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
What NZMS Diabetes does
NZMS Diabetes (legal name: New Zealand Medical & Scientific Limited) is a wholly-owned subsidiary of Dexcom, Inc. (NASDAQ: DXCM) and operates as the exclusive distributor of Dexcom continuous glucose monitoring (CGM) systems and Tandem Diabetes Care insulin pump products in New Zealand. Headquartered in Auckland with 51-100 employees, the company has served the New Zealand diabetes community for over 20 years and provides a portfolio spanning Dexcom G7 and ONE+ CGM sensors, the t:slim X2 insulin pump with Control-IQ+ hybrid closed-loop and Basal-IQ predictive low-glucose suspend technology, the Tandem t:slim Mobile App, and supporting data platforms (Dexcom Clarity, Glooko, Tandem Source) plus consumables including infusion sets and pump accessories. The technology stack integrates CGM with closed-loop insulin delivery and offers interoperability with Garmin wearables and Apple Watch.
The company's business model is anchored by Pharmac, New Zealand's national drug procurement agency, which approved full funding of CGM and insulin pump systems for all ~27,800 New Zealanders with Type 1 diabetes in October 2024. NZMS sells primarily through a healthcare provider-led GTM where patients obtain Special Authority prescriptions from GPs or diabetes specialists and fill them through local pharmacies; a direct-to-consumer online shop (shop.nzmsdiabetes.co.nz) handles accessories and non-funded supplies. Go-to-market is reinforced by community-led demand generation through the Dexcom Warriors program (20,000+ global advocates) and partnerships with Diabetes New Zealand and No More Fear NZ. Revenue is generated from hardware sales (CGM devices, pumps, consumables) supplemented by Pharmac reimbursement under long-term funding contracts, with private-pay pricing available for non-funded patients. Specific revenue figures are not publicly disclosed.
NZMS Diabetes firmographics
Firmographics- Name
- NZMS Diabetes
- Legal name
- New Zealand Medical & Scientific Limited
- Website
- https://nzmsdiabetes.co.nz
- Company type
- Private
- Founded year
- 1982
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- NZMS Diabetes is a wholly-owned Dexcom subsidiary that exclusively distributes Dexcom CGM systems and Tandem insulin pumps to New Zealanders with Type 1 diabetes through Pharmac-funded prescriptions and local pharmacies.
- Ownership category
- akta.pro rank
NZMS Diabetes industry classification
Industry- Product category
- Diabetes Management Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
- akta.pro secondary industries
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE), Type 1 Diabetes Care (HLAKADAB), Diabetes (General) (HLAKADAA)
Keywords
Where NZMS Diabetes is headquartered
LocationHeadquarters
- HQ city
- Auckland
- HQ country
- New Zealand
- HQ region
- Oceania
Offices2 records
Markets served
NZMS Diabetes business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- CGM Device Sales: Sale of Dexcom G7, Dexcom ONE+, and Dexcom G6 continuous glucose monitoring systems including sensors, transmitters, and optional receivers.
- Insulin Pump Sales: Sale of Tandem t:slim X2 insulin pumps with Control-IQ+ or Basal-IQ technology.
- Consumables: Recurring revenue from cartridges, infusion sets (AutoSoft 90, AutoSoft 30, TruSteel, VariSoft), and replacement sensors sold through pharmacies and online shop.
- Accessories: Sale of accessories including t:case protective cases, screen protectors, t:holster rotating belt clips, and travel/insurance documentation.
- Pharmac Funding: Government reimbursement through Pharmac for eligible Type 1 diabetes patients covering CGMs, insulin pumps, and consumables under Special Authority criteria.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Pharmac Funded - Eligible Type 1 Diabetes Patients |
| Unit Pricing | Pay-as-you-go | Private Pay - Non-Funded Patients |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
NZMS Diabetes product offering
Product offeringCore offering
NZMS Diabetes is the New Zealand exclusive distributor of Dexcom continuous glucose monitoring systems (Dexcom G7, Dexcom G6, and Dexcom ONE+) and Tandem t:slim X2 insulin pumps featuring Control-IQ+ and Basal-IQ algorithms. The company sells the hardware devices, recurring consumables (sensors, infusion sets, cartridges), accessories, and complementary data management software (Dexcom Clarity, Glooko) to individuals living with diabetes, primarily funded through Pharmac for Type 1 diabetes patients and supplied through local pharmacies on prescription.
Product overview
NZMS Diabetes is a New Zealand subsidiary of Dexcom that distributes a comprehensive diabetes management product portfolio. The core offerings include Dexcom continuous glucose monitoring systems (G7 and ONE+) and Tandem t:slim X2 insulin pumps with two technology tiers (Control-IQ+ advanced hybrid closed-loop and Basal-IQ predictive suspend). These are complemented by data management software including Dexcom Clarity for CGM analytics and Glooko Diasend for cross-device glucose and insulin data integration. Supporting accessories include infusion sets (AutoSoft 90/30, TruSteel, VariSoft) and pump cases. The portfolio enables connected diabetes management through integration with Garmin wearables, Tandem Source cloud platform, and smartphone apps including Apple Watch compatibility. All products are distributed in New Zealand with Pharmac funding support available for eligible patients with type 1 diabetes.
Differentiator
Problem solved
Functional benefit
Products and services
- Dexcom G7 Continuous Glucose Monitoring System Advanced continuous glucose monitoring system with predictive alerts, 30-minute warm-up, 12-hour grace period, and no fingerpricks required. Features a 60% smaller all-in-one wearable design and integrates with Tandem t:slim X2 insulin pumps. Distributed in New Zealand to people with diabetes aged 2 years and older, with Pharmac funding available for eligible Type 1 diabetes patients.
- Dexcom ONE+ Continuous Glucose Monitoring System Easy-to-use continuous glucose monitoring system with essential alerts, designed specifically for people living with type 2 diabetes. Provides real-time glucose readings without fingerpricks and is funded by Pharmac as a standalone CGM option for eligible patients.
- t:slim X2 Insulin Pump with Control-IQ+ Technology Insulin pump with Control-IQ+ advanced hybrid closed-loop technology that predicts glucose levels 30 minutes ahead and automatically adjusts insulin delivery to prevent both highs and lows. Features a colour touchscreen, rechargeable battery, and remote software updates. Indicated for users aged 2+ weighing 9-200 kg and integrates with Dexcom G7 and G6 CGM systems.
- t:slim X2 Insulin Pump with Basal-IQ Technology Insulin pump with Basal-IQ predictive low-glucose suspend technology that predicts glucose 30 minutes ahead and suspends insulin delivery if levels are expected to drop below 4.4 mmol/L. Used by people with Type 1 diabetes who prefer pump therapy with automated low-glucose protection.
- Dexcom Clarity Web-based data analysis platform for healthcare professionals and home users to review, analyse, and evaluate historical CGM data from Dexcom G7 and G6 systems to support diabetes management decisions. Integrated into the Dexcom G7 mobile app.
- Glooko (Diasend) Diabetes Data Management Software Web-based diabetes management software that transmits, stores, and monitors patient glucose readings and insulin doses from multiple devices including the t:slim X2 insulin pump, Dexcom G6/G7, and various glucose meters. Presents data in graphs, tables, and statistics; compatible with Windows 7/8/10 and macOS 10.9-10.12. Recommended data management platform for NZMS Diabetes customers.
- Tandem Source Cloud-based web application for uploading and viewing diabetes therapy data from t:slim X2 insulin pumps, with three easy-to-read reports for therapy analysis. No installation required; allows users to share pump data with healthcare clinics for therapy adjustments.
- Tandem t:slim Mobile App Mobile application for iOS and Android that connects wirelessly to the t:slim X2 insulin pump to enable discreet bolusing from the smartphone. Displays insulin on board, current carbohydrate data, glucose levels, and pump notifications, and automatically uploads data to the Tandem Source platform.
- AutoSoft 90 Infusion Set Infusion set with automatic inserter for the t:slim X2 insulin pump, featuring a soft, flexible cannula with a single adhesive site and up to 72-hour wear time. Sold as a recurring consumable via pharmacies and the NZMS online shop.
- AutoSoft 30 Infusion Set Infusion set with automatic inserter at a 30-degree insertion angle for the t:slim X2 insulin pump. Sold as a recurring consumable via pharmacies and the NZMS online shop.
- TruSteel Infusion Set Steel cannula infusion set for the t:slim X2 insulin pump requiring manual insertion. Sold as a recurring consumable via pharmacies and the NZMS online shop.
- VariSoft Infusion Set Variable-angle soft cannula infusion set for subcutaneous insulin infusion with the t:slim X2 pump. Sold as a recurring consumable via pharmacies and the NZMS online shop.
- t:case Pump Case Protective plastic case with stainless steel clip for the t:slim X2 insulin pump, allowing vertical, horizontal, or clip-less wearing. Sold as an accessory via the NZMS online shop.
- t:holster Rotating Belt Clip Durable plastic case with a 360-degree rotating clip for the t:slim X2 pump, allowing flexible vertical or horizontal wearing. Sold as an accessory via the NZMS online shop.
- t:slim X2 Screen Protector Pack of two screen protectors for the t:slim X2 insulin pump touchscreen. Sold as an accessory via the NZMS online shop.
- MedAngel ONE Temperature Sensor Bluetooth temperature sensor that monitors the temperature of temperature-sensitive medications such as insulin. Connects to the MedAngel ONE smartphone app with a medication database and alerts users when medications fall outside their optimal temperature range. Distributed in New Zealand by NZMS Diabetes.
Quantifiable outcome
- 31% relative reduction in sensor time below 3.9 mmol/L with Basal-IQ technology
- +3 more outcomes
Companies that use NZMS Diabetes
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
NZMS Diabetes technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
Feature7 records
NZMS Diabetes partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, flagship and minor.
- GarmincoreDexcom G6 and Dexcom G7 CGM systems are now compatible with selected Garmin devices including sports watches and cycle computers. Allows users to view glucose levels on Garmin devices during activities, simplifying diabetes management for active users.
- Diabetes New ZealandflagshipPartnership announced April 2023 to improve access and awareness to diabetes technology in New Zealand. Brings together expertise and resources of both organizations to drive campaigns for improved access to diabetes technology and better health outcomes for people living with type 1, type 2 and gestational diabetes.
- MedAngelminorNZMS Diabetes distributes MedAngel ONE, a Bluetooth temperature sensor designed to monitor temperature-sensitive medications like insulin. The sensor connects to a smartphone app and alerts users when medications are outside optimal temperature range.
- Tandem Diabetes CarecorePartnership to introduce the t:slim X2 insulin pump to New Zealand market. NZMS Diabetes distributes Tandem's insulin pumps which integrate with Dexcom CGM systems. Features include Control-IQ+ hybrid closed-loop technology and Basal-IQ predictive low-glucose suspend.
- Valeritas HoldingsminorExclusive distribution agreement for Valeritas products for type 2 diabetes patients in New Zealand. Valeritas retained responsibility for product development, regulatory approval, quality management and manufacturing while NZMS handled sales, marketing, customer support and distribution.
- DexcomcoreDexcom, Inc. (Nasdaq: DXCM) acquired NZMS Diabetes making New Zealand Medical & Scientific Limited a Dexcom subsidiary. This ownership provides NZMS with access to Dexcom's leading CGM technology portfolio including G7, G6, and ONE+ systems, global resources, and innovation pipeline.
- No More Fear NZcoreCommunity-based organization founded by Lavina Good and Toby Good that advocates for all New Zealanders living with type 1 diabetes. NZMS Diabetes supports their efforts to empower the type 1 diabetes community and improve access to CGM technology.
- GlookocoreGlooko diabetes management software is the recommended platform for NZMS Diabetes customers to upload, store, and monitor glucose readings and insulin pump data. Compatible with t:slim X2, Dexcom G6/G7, and various glucose meters.
Scale indicators8 records
Recent moves13 records
Expansion highlights5 records
NZMS Diabetes competitors and assessment
Company assessmentDirect peers
- Abbott Diabetes Care (FreeStyle Libre): Global leader in flash glucose monitoring (FreeStyle Libre) and a direct competitor to Dexcom's CGM. Operates in New Zealand and competes for the same Type 1 and Type 2 diabetes patients, with FreeStyle Libre a credible alternative that could be added to Pharmac's funded list.
- Medtronic Australasia (Diabetes): Sells insulin pumps (MiniMed) and CGM systems (Guardian) in ANZ, including the 780G hybrid closed-loop system. Directly competes with Tandem t:slim X2 / Control-IQ+ for the same T1D patient and healthcare professional audience in New Zealand.
- AMSL Diabetes (Australia): Australian counterpart of NZMS Diabetes and sister subsidiary under Dexcom, Inc. Distributes the same Dexcom CGM and Tandem t:slim X2 portfolio in Australia. Closest functional peer by product mix, GTM, and parent ownership.
- Ypsomed Australia: Distributes the mylife YpsoPump insulin pump across Australia and New Zealand. Competes with Tandem t:slim X2 in the insulin pump segment and is an alternative for healthcare professionals evaluating pump choices.
Broad incumbents
- Roche Diabetes Care: Major diabetes care incumbent offering blood glucose meters, insulin delivery systems, and digital diabetes management. Operates broadly across the diabetes category and competes with NZMS's broader portfolio of monitoring and therapy products.
- Tandem Diabetes Care: Manufacturer of the t:slim X2 insulin pump that NZMS distributes in New Zealand. As the technology partner, Tandem's product strategy (Control-IQ+, t:slim Mobile App, future hardware) directly shapes NZMS's competitive position.
- Dexcom, Inc. (parent): NZMS's parent company and global leader in CGM technology. As the manufacturer of NZMS's flagship products, Dexcom defines NZMS's product roadmap, brand positioning, and ultimately the value NZMS can capture in New Zealand.
- LifeScan (Johnson & Johnson MedTech): Established player in blood glucose monitoring with OneTouch meters used by many people with diabetes. Overlaps with NZMS's broader diabetes management category though not focused on CGM or pumps.
Emerging players
- Insulet Corporation (Omnipod): Maker of the Omnipod patch pump, an emerging alternative to tubed pumps like Tandem t:slim X2. Omnipod is gaining traction globally in T1D and could enter the NZ market or be listed on Pharmac as an alternative pump system.
Others
- Diabetes New Zealand: National advocacy partner of NZMS Diabetes focused on improving access and awareness to diabetes technology. Not a commercial competitor but a key ecosystem participant influencing demand, policy, and patient education in New Zealand.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
NZMS Diabetes social profiles
Digital presenceNZMS Diabetes financial estimates
Financial estimateRevenue estimate
Valuation estimate
NZMS Diabetes leadership team
Management profileNumber of profiles
Profiles2 records
NZMS Diabetes funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NZMS Diabetes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NZMS Diabetes
What does NZMS Diabetes do?
NZMS Diabetes is the New Zealand exclusive distributor of Dexcom continuous glucose monitoring systems (Dexcom G7, Dexcom G6, and Dexcom ONE+) and Tandem t:slim X2 insulin pumps featuring Control-IQ+ and Basal-IQ algorithms. The company sells the hardware devices, recurring consumables (sensors, infusion sets, cartridges), accessories, and complementary data management software (Dexcom Clarity, Glooko) to individuals living with diabetes, primarily funded through Pharmac for Type 1 diabetes patients and supplied through local pharmacies on prescription.
Is NZMS Diabetes a public or private company?
NZMS Diabetes is a private company. It is classified as corporate owned and is currently operating.
When was NZMS Diabetes founded?
NZMS Diabetes was founded in 1982. It employs 51 to 100 people.
Where is NZMS Diabetes based?
NZMS Diabetes is headquartered in Auckland, New Zealand, in the Oceania region.
How does NZMS Diabetes make money?
Five revenue lines are on record. CGM Device Sales are the primary driver. The others are insulin Pump Sales, consumables, accessories and pharmac Funding.
Who are NZMS Diabetes's main competitors?
Direct peers on record are Abbott Diabetes Care (FreeStyle Libre), Medtronic Australasia (Diabetes), AMSL Diabetes (Australia) and Ypsomed Australia. Broad incumbents are Roche Diabetes Care, Tandem Diabetes Care, Dexcom, Inc. (parent) and LifeScan (Johnson & Johnson MedTech). Insulet Corporation (Omnipod) is listed as an emerging player. Diabetes New Zealand is listed as an others.
Does NZMS Diabetes have an API?
No public API is recorded for NZMS Diabetes.
What industry is NZMS Diabetes in?
NZMS Diabetes's product category is Diabetes Management Devices. Its primary akta.pro industry code is CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers), with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 339113 and its SIC code is 5047.